About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
T
Outcomes of Patients With CLL and COVID-19 Infection
By
ERIC 2022 - European Research Initiative on CLL - ERIC
FEATURING
Thomas Chatzikonstantinou
November 9, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:18
Treatment Considerations in CLL: Challenging Patient Cases
Treatment Considerations for Ibrutinib-Intolerant Patients - A Patie…
Feat.
M. Shadman
Featured Video
23:48
Tumor Lysis Syndrome
Strategies for Preventing and Managing Tumor Lysis Syndrome-Associat…
Feat.
M. Geyer
Related Content
AUTOPLAY
ON
Medtronic
Extraspinal & Peripheral Bone Ablation: Clinical Case Review
Fri, Dec 11, 2020
Faculty:
Osman Ahmed
,
Medtronic .
,
Jason Levy
,
Jonathan Morris
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
24:33
Indy Hematology Review
Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…
Feat.
J. Woyach
10:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…
Feat.
J. Woyach
06:34
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…
Feat.
A. Kittai
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
13:16
ASH 2022 Conference Coverage
Experts Discuss Key Updates in CLL
Feat.
S. O'Brien,
C. Coombs
10:35
Alan Skarbnik
Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…
28:43
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Scripps MD Anderson Cancer Center Updates on CLL/SLL Frontline Thera…
Feat.
S. O'Brien
06:28
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…
Feat.
O. Al-Sawaf
16:16
Insights from 2023 EHA® Annual Meeting
Experts Discuss Key Updates in CLL From EHA and iCML
Feat.
S. O'Brien,
C. Coombs
14:05
The University of Kansas Cancer Center
Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untrea…
Feat.
M. Hoffmann
06:21
City of Hope
Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL
Feat.
A. Danilov
09:27
RWJBarnabas Health Rutgers Cancer Institute of New Jersey
Fixed Duration Treatment in CLL
Feat.
J. Kra
04:14
ecancer
ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…
Feat.
J. Brown
18:04
Seema Bhat
Zanubrutinib for the Treatment of CLL: Learnings From ALPINE, SEQUOI…
06:53
Fred Hutchinson Cancer Center
Surveying Safety and Efficacy Data in R/R CLL: ALPINE and ELEVATE-RR…
Feat.
M. Shadman
14:56
ACHL
Frontline Treatment of Older CLL Patients
Feat.
S. Parikh
05:22
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Five-Year Follow-Up Update of Defined-Com…
Feat.
E. Liang
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
